Kiniksa Pharmaceuticals, Ltd.
(NASDAQ:KNSA)
$15.70
-0.13 (-0.82%)
At Close: 4:00 PM
KNSA Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
KNSA Stock Price Today
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock declined over -1.69% intraday to trade at $15.7 a share on NASDAQ. The stock opened with a loss of -3.98% at $15.20 and touched an intraday high of $15.45, falling -0.82% against the last close of $15.83. The Kiniksa Pharmaceuticals, Ltd. in stock market went to a low of $14.66 during the session.
KNSA Stock Snapshot
$15.83
Prev. Close
1.1 Billion
Market Cap
$14.66
Day Low
$15.20
Open
N/A
Number of Shares
$15.45
Day High
N/A
P/E ratio
-0.10
EPS (TTM)
2.86
Cash Flow per Share
N/A
Free Float in %
5.76
Book Value
163258.00
Volume
KNSA Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta-0.17
Sales or Revenue$248.75 Million
5Y Sales Change94.25%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Peers
Frequently Asked Questions
What is the current Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price?
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) stock price is $15.70 in the last trading session. During the trading session, KNSA stock reached the peak price of $15.45 while $14.66 was the lowest point it dropped to. The percentage change in KNSA stock occurred in the recent session was -1.69% while the dollar amount for the price change in KNSA stock was -$0.27.
KNSA's industry and sector of operation?
The NASDAQ listed KNSA is part of Biotechnology industry that operates in the broader Healthcare sector. Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Who are the executives of KNSA?
Mr. Chad Morin
Senior Vice President & Chief Compliance Officer
Ms. Madelyn Zeylikman
SVice President, Gen. Counsel & Sec.
Mr. Michael R. Megna CPA
Chief Accounting Officer & Group Vice President of Fin.
Ms. Mei Jang
Senior Vice President of Technical Operations
How KNSA did perform over past 52-week?
KNSA's closing price is 0.84% higher than its 52-week low of $10.29 where as its distance from 52-week high of $20.65 is -0.21%.
How many employees does KNSA have?
Number of KNSA employees currently stands at N/A. KNSA operates from Clarendon House, Hamilton, HM 11, BM.
Link for KNSA official website?
Official Website of KNSA is: https://www.kiniksa.com
How do I contact KNSA?
KNSA could be contacted at phone #7814399100 and can also be accessed through its website. KNSA operates from Clarendon House, Hamilton, HM 11, BM.
How many shares of KNSA are traded daily?
KNSA stock volume for the day was 163258.00 shares. The average number of KNSA shares traded daily for last 3 months was 336.31 Thousands.
What is the market cap of KNSA currently?
The market value of KNSA currently stands at $1.1 Billion with its latest stock price at $15.70 and N/A of its shares outstanding.